pH-Responsive hyaluronic acid-enveloped ZIF-8 nanoparticles for anti-atherosclerosis therapy

Obaid, Essam Abdo Mohammed Saad; Wu, Shuai; Zhong, Yuan; Meng, Yan; Zhu, Li; Li, Bibo; Wang, Yi; Wu, Wei; Wang, Guixue

doi:10.1039/d2bm00603k

Cited by 21 publications

(12 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Essam et al coated HA on simvastatin (SIM) in a zeolitic imidazolate framework-8 (ZIF-8) (SIM/ZIF-8) in an aqueous solution via electrostatic interactions. [79] The specific binding ability of HA to the cluster of differentiation 44 (CD44) receptor, [80] has facilitated the development of several targeted nanoplatforms for the treatment of AS. These are highlighted in Section 5 of this review.…”

Section: Hyaluronic Acid-derived Nanomaterialsmentioning

confidence: 99%

“…Reproduced with permission. [ 79 ] Copyright 2022, Royal Society of Chemistry. B) a) Schematic representation of the pH‐responsive HR RAP NPs that release ATR and RAP at the intima and intracellular spaces.…”

Section: Therapeutic Strategies For Asmentioning

confidence: 99%

“…[136] Based on this low pH, Essam et al used a one-step self-assembly method to effectively encapsulate the hypolipemiant SIM in ZIF-8. [79] Based on the pH-sensitive properties of ZIF-8-derived NPs, SIM/ZIF-8 was degraded in the atherosclerotic microenvironment ensuring a controlled release of the loaded drugs. After incubation for 48 h at pH 5, 87.5% of the SIM was released from SIM/ZIF-8 due to the disruption of the coordination bonds between the zinc ions and ZIF-8′s 2methylimidazole in an acidic environment.…”

Section: Ph-responsive Strategiesmentioning

confidence: 99%

“…The release of the active substance within this NPs was evaluated using a fluorescence resonance energy transfer probe. After the [79] Copyright 2022, Royal Society of Chemistry. B) a) Schematic representation of the pH-responsive HR RAP NPs that release ATR and RAP at the intima and intracellular spaces.…”

Section: Enzyme-responsive Strategiesmentioning

confidence: 99%

mentioning

confidence: 99%

See 4 more Smart Citations

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Xiao,

Li,

Xiong

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Atherosclerosis, the leading cause of death worldwide, is responsible for ≈17.6 million deaths globally each year. Most therapeutic drugs for atherosclerosis have low delivery efficiencies and significant side effects, and this has hampered the development of effective treatment strategies. Diversified nanomaterials can improve drug properties and are considered to be key for the development of improved treatment strategies for atherosclerosis. The pathological mechanisms underlying atherosclerosis is summarized, rationally designed nanoparticle‐mediated therapeutic strategies, and potential future therapeutic targets for nanodelivery. The content of this study reveals the potential and challenges of nanoparticle use for the treatment of atherosclerosis and highlights new effective design ideas.

show abstract

Section: Hyaluronic Acid-derived Nanomaterialsmentioning

confidence: 99%

Section: Therapeutic Strategies For Asmentioning

confidence: 99%

Section: Ph-responsive Strategiesmentioning

confidence: 99%

Section: Enzyme-responsive Strategiesmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Xiao,

Li,

Xiong

et al. 2023

Advanced Science

View full text Add to dashboard Cite

show abstract

Advances in the treatment of atherosclerosis with ligand‐modified nanocarriers

Deng,

Wang,

et al. 2023

Exploration

View full text Add to dashboard Cite

Atherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well‐being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface‐modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over‐expressed in atherosclerotic conditions. This paper reviews recent research (2018–present) advances in various ligand‐modified nanoparticle systems targeting atherosclerosis by specifically targeting signature molecules in the hope of precise treatment at the molecular level and concludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis.

show abstract

Hyaluronic Acid Receptor‐Mediated Nanomedicines and Targeted Therapy

Ouyang,

Zhao,

et al. 2024

Small Methods

View full text Add to dashboard Cite

Hyaluronic acid (HA) is a naturally occurring polysaccharide found in the extracellular matrix with broad applications in disease treatment. HA possesses good biocompatibility, biodegradability, and the ability to interact with various cell surface receptors. Its wide range of molecular weights and modifiable chemical groups make it an effective drug carrier for drug delivery. Additionally, the overexpression of specific receptors for HA on cell surfaces in many disease states enhances the accumulation of drugs at pathological sites through receptor binding. In this review, the modification of HA with drugs, major receptor proteins, and the latest advances in receptor‐targeted nano drug delivery systems (DDS) for the treatment of tumors and inflammatory diseases are summarized. Furthermore, the functions of HA with varying molecular weights of HA in vivo and the selection of drug delivery methods for different diseases are discussed.

show abstract

pH-Responsive hyaluronic acid-enveloped ZIF-8 nanoparticles for anti-atherosclerosis therapy

Abstract: Nanomedicines represent the new promise strategies for treating atherosclerosis (AS). Because they enhance drug bioavailability and have lower side effects. Nevertheless, nanomedicines have several challenges with these advantages, including a...

Cited by 21 publications

References 42 publications

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Advances in the treatment of atherosclerosis with ligand‐modified nanocarriers

Hyaluronic Acid Receptor‐Mediated Nanomedicines and Targeted Therapy

Contact Info

Product

Resources

About